Federal Circuit dances with biosimilar law's complexity in Zarxio fight
This article was originally published in Scrip
While the case before the US Court of Appeals for the Federal Circuit on 3 June was a dispute between Amgen and Novartis' Sandoz unit over how soon the latter firm should be able to market its biosimilar medicine Zarxio (filgrastim-sndz), it was the knotty intricacies of the Biologics Price Competition and Innovation Act (BPCIA) – the law that created the regulatory pathway for the FDA to approve biosimilars – that was on trial.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.